AMAG Pharmaceuticals, Inc. (AMAG): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMAG Price/Volume Stats
| Current price | $13.75 | 52-week high | $13.80 |
| Prev. close | $13.73 | 52-week low | $4.41 |
| Day low | $13.75 | Volume | 1,534,500 |
| Day high | $13.76 | Avg. volume | 950,664 |
| 50-day MA | $12.08 | Dividend yield | N/A |
| 200-day MA | $9.17 | Market Cap | 477.47M |
AMAG Stock Price Chart Interactive Chart >
AMAG Pharmaceuticals, Inc. (AMAG) Company Bio
AMAG Pharmaceuticals has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. The company was founded in 1981 and is based in Waltham, Massachusetts.
Latest AMAG News From Around the Web
Below are the latest news stories about Amag Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMAG as an investment opportunity.
Covis takes out Amag Pharma for $498MApollo Global Management portfolio company Covis Group S.à r.l. has agreed to acquire AMAG Pharmaceuticals ([[AMAG]] +43.9%) for $13.75 per share in cash. The total transaction value is ~$498M on a fully diluted basis or ~$647M on an enterprise basis including debt.The tender offer for AMAG shares will commence this... |
AMAG Pharma up 41% on takeover rumorAMAG Pharmaceuticals (AMAG) jumps 41% after hours in apparent response to rumors that Apollo Global (APO) portfolio company Covis Pharma is about to acquire the company.Covis is a Netherlands-based specialty pharmaceutical company that only months ago was purchased by Apollo for an undisclosed sum.It's been a rough few years for AMAG, which... |
AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseAMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New ZealandAgreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantagWALTHAM, Mass. and AMSTERDAM, The Netherlands, July 23, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Norgine B.V., a leading European specialist pharmaceutical company, today announced they have entered into an exclusive licensing agreement to develop and commercialize ciraparantag in Europe, Australia and New Zealand. Ciraparantag is in development for use in patients treated with direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) when reversal of the anticoagulant effect of these products is needed f... |
When Will AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Breakeven?AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG): AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops... |
AMAG Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 78.34% |
| 5-year | -43.18% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -19.88% |
| 2018 | 14.64% |
Continue Researching AMAG
Want to see what other sources are saying about Amag Pharmaceuticals Inc's financials and stock price? Try the links below:Amag Pharmaceuticals Inc (AMAG) Stock Price | Nasdaq
Amag Pharmaceuticals Inc (AMAG) Stock Quote, History and News - Yahoo Finance
Amag Pharmaceuticals Inc (AMAG) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...